fidaxomicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
aminoglycosides, antibiotics obtained from various Micromonospora 4180 873857-62-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lipiarmicin
  • lipiarmycin
  • tiacumicin B
  • dificid
  • fidaxomicin
  • dificlir
Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. In vitro, fidaxomicin is active primarily against species of clostridia, including Clostridium difficile by inhibiting RNA synthesis by RNA polymerases.
  • Molecular weight: 1058.05
  • Formula: C52H74Cl2O18
  • CLOGP: 7.19
  • LIPINSKI: 4
  • HAC: 18
  • HDO: 7
  • TPSA: 266.66
  • ALOGS: -4.93
  • ROTB: 15
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 32
kinase-selectivity-class AXL,GRK2,MAP2K6 3
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 2, 2018 PMDA Astellas Pharma Inc
May 27, 2011 FDA CUBIST PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 193.29 30.02 58 1901 36187 90590301
Disease recurrence 128.86 30.02 43 1916 37610 90588878
Drug ineffective 73.05 30.02 116 1843 1384182 89242306
Clostridium test positive 72.89 30.02 18 1941 5383 90621105
Avian influenza 58.96 30.02 8 1951 78 90626410
Clostridium difficile colitis 58.79 30.02 22 1937 26684 90599804
Cytomegalovirus viraemia 52.96 30.02 15 1944 7571 90618917
Pseudomembranous colitis 47.72 30.02 12 1947 3856 90622632
Renal graft infection 46.95 30.02 8 1951 378 90626110
Klebsiella test positive 41.67 30.02 9 1950 1494 90624994
Urinary tract infection pseudomonal 39.69 30.02 8 1951 950 90625538
Weaning failure 37.88 30.02 7 1952 527 90625961
Diarrhoea 33.87 30.02 67 1892 939123 89687365
Peptic ulcer perforation 32.46 30.02 6 1953 452 90626036
Parvovirus infection 31.95 30.02 6 1953 493 90625995
Fluid balance positive 31.19 30.02 4 1955 24 90626464
No adverse event 31.18 30.02 19 1940 67963 90558525
Epstein-Barr viraemia 30.81 30.02 7 1952 1463 90625025
Hypovolaemia 30.13 30.02 11 1948 12420 90614068

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 105.80 47.68 34 1048 22625 42597628
Agranulocytosis 69.89 47.68 27 1055 30585 42589668
Megacolon 62.96 47.68 14 1068 2271 42617982
Drug ineffective 58.54 47.68 75 1007 630122 41990131
Diarrhoea 54.29 47.68 62 1020 460787 42159466
Pathogen resistance 48.54 47.68 16 1066 11434 42608819

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Clostridium difficile infection 238.35 33.74 77 2727 52052 110534443
Drug ineffective 103.14 33.74 156 2648 1520384 109066111
Disease recurrence 88.80 33.74 39 2765 60745 110525750
Clostridium difficile colitis 87.10 33.74 35 2769 43743 110542752
Pseudomembranous colitis 71.75 33.74 19 2785 6372 110580123
Clostridium test positive 70.31 33.74 21 2783 10872 110575623
Diarrhoea 60.44 33.74 105 2699 1139400 109447095
Megacolon 59.00 33.74 15 2789 4290 110582205
Agranulocytosis 57.35 33.74 29 2775 61731 110524764
Avian influenza 54.94 33.74 8 2796 113 110586382
Septic shock 51.81 33.74 38 2766 157490 110429005
Cytomegalovirus viraemia 48.89 33.74 18 2786 17746 110568749
Pneumonia aspiration 42.09 33.74 26 2778 81207 110505288
Renal graft infection 40.06 33.74 8 2796 771 110585724
Drug reaction with eosinophilia and systemic symptoms 39.32 33.74 25 2779 82070 110504425
Pathogen resistance 38.15 33.74 15 2789 17657 110568838
Treatment failure 36.78 33.74 40 2764 277194 110309301

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A07AA12 ALIMENTARY TRACT AND METABOLISM
ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
INTESTINAL ANTIINFECTIVES
Antibiotics
FDA CS M0028311 Macrolides
FDA EPC N0000175431 Macrolide Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:37416 EC 2.7.7.6 (RNA polymerase) inhibitor
CHEBI has role CHEBI:76969 bacterial metabolite

Related Drugs by ATC class:

A07AA Antibiotics 12 drugs
amphotericin BcolistinkanamycinnatamycinneomycinnystatinparomomycinPolymyxin Brifamycinrifaximinstreptomycinvancomycin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Clostridium difficile infection indication 186431008
Pseudomembranous enterocolitis indication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.95 acidic
pKa2 9.53 acidic
pKa3 11.96 acidic
pKa4 12.76 acidic
pKa5 13.32 acidic
pKa6 13.74 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 7906489 March 4, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 7906489 March 4, 2027 TREATMENT OF MICROBIAL INFECTIONS
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL 7906489 March 4, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 8859510 July 31, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL 8859510 July 31, 2027 TREATMENT OF MICROBIAL INFECTIONS
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL 8859510 July 31, 2027 TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
200MG DIFICID CUBIST PHARMS LLC N201699 May 27, 2011 RX TABLET ORAL Jan. 24, 2027 PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)
40MG/ML DIFICID CUBIST PHARMS LLC N213138 Jan. 24, 2020 RX FOR SUSPENSION ORAL Jan. 24, 2027 PEDIATRIC PATIENTS AGED 6 MONTHS AND OLDER FOR THE TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA (CDAD)

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
DNA-directed RNA polymerase Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4030846 VUID
N0000182832 NUI
D09394 KEGG_DRUG
4030846 VANDF
FI8 PDB_CHEM_ID
CHEMBL1255800 ChEMBL_ID
CHEMBL445546 ChEMBL_ID
10909 IUPHAR_LIGAND_ID
DB08874 DRUGBANK_ID
Z5N076G8YQ UNII
1111103 RXNORM
181510 MMSL
27891 MMSL
385338 MMSL
d07778 MMSL
013814 NDDF
703664004 SNOMEDCT_US
703665003 SNOMEDCT_US
C0065023 UMLSCUI
D000077732 MESH_DESCRIPTOR_UI
CHEBI:68590 CHEBI
9038 INN_ID
10034073 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fidaxomicin HUMAN PRESCRIPTION DRUG LABEL 1 0480-2596 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
Fidaxomicin HUMAN PRESCRIPTION DRUG LABEL 1 13668-745 TABLET, FILM COATED 200 mg ORAL ANDA 22 sections
Dificid HUMAN PRESCRIPTION DRUG LABEL 1 52015-080 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
Dificid HUMAN PRESCRIPTION DRUG LABEL 1 52015-080 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
DIFICID HUMAN PRESCRIPTION DRUG LABEL 1 52015-700 GRANULE, FOR SUSPENSION 200 mg ORAL NDA 30 sections
DIFICID HUMAN PRESCRIPTION DRUG LABEL 1 52015-700 GRANULE, FOR SUSPENSION 200 mg ORAL NDA 30 sections
Fidaxomicin HUMAN PRESCRIPTION DRUG LABEL 1 60505-4833 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections